GLP-1 receptor agonist
Semaglutide
The most studied GLP-1 medication, prescribed by independently licensed providers and prepared by licensed compounding pharmacies.
- 15 to 20% average body-weight reduction over 12 to 18 months in clinical trials, when paired with lifestyle support
- Prepared by a state-licensed 503A compounding pharmacy
- Flexible compounded dosing for tolerance and titration
$149/mo · flat at every dose
or $379/quarter




